97 results about "Metabolic profile" patented technology

An apparatus and method analyzes a metabolic profile in a biological sample. The apparatus includes an input unit for inputting the drugs and/or metabolites to be screened; a controlling unit for determining a parameter set for metabolites preparation and for mass spectrometry analysis depending on the input of the kind of metabolites to be screened; a treatment unit for preparing the metabolites to be screened depending on the determined parameter set; a mass spectrometer for performing mass spectrometry analysis on prepared metabolites depending on the parameter set; a database for storing results of analyzing and parameter sets for metabolite preparation and for mass spectrometry analyses; and an evaluation unit for evaluating the results of mass spectrometry by use of reference results stored in the database to output an analysis of the metabolites profile.

The metabolic processes involved in the formation of any glucose-based metabolite of a metabolic network are determined. A precursor molecule is labeled with a stable carbon (¹³C) isotope at specific positions. The label is allowed to distribute and rearrange in the system. Metabolites are recovered and analyzed against a control system to determine a set of metabolic pathway substrate fluxes caused by changes to the test system relative to the control system such as the addition of compound being tested as a potential drug.

The invention provides methods for characterizing metabolic profiles, phenotypic profiles and trait profiles in plants or groups of plants. Additionally, methods for establishing an unbiased model between a phenotypic profile and a metabolic profile, or between a trait profile and metabolic profile, are also provided by the invention. Further, methods for using such unbiased models to accurately predict the development of a phenotype of interest or a trait of interest in an independent, immature plant are also provided. In one embodiment, immature plants are selected for use based on their predicted development of a phenotype or trait of interest.

The invention discloses an LC/MS (liquid chromatography-mass spectrometer) metabonomics analysis method based on serum of a GDM (gestational diabetes mellitus) patient. The method comprises the steps as follows: serum samples of a normal pregnant woman and a pregnant woman with GDM are collected, processed and separated by a chromatographic column, and mass spectrometric detection analysis is adopted; original data of an instrument is extracted and aligned after LC/MS detection analysis, and data free of noise disturbance and capable of being used for statistical analysis is obtained; and a multi-dimensional statistical model is established and visually displays metabolic profiling difference between the two groups, so that differential metabolites of the two groups are obtained, and the substances are subjected to preliminary evaluation. With the adoption of the method, the variation condition of the metabolites of the GDM patient can be presented comprehensively and synthetically, and the method can be used for providing powerful technical support for early diagnosis and prognosis of GDM.

Cancer stem cells exhibit different metabolic profiles from other cancer cells, such that they do not readily respond to treatment using conventional chemotherapeutic agents. Studies disclosed herein now demonstrate that the glycylcycline antibiotic tigecycline (a tetracycline derivative) exhibits anti-cancer activity, including activity against cancer stem cells. This anti-neoplastic activity appears to be due to inhibition of mitochondrial protein synthesis in the cancer cells. In preferred embodiments, the cancer to be treated is a hematological cancer, such as leukemia, lymphoma or myeloma.

This invention is directed, inter alia, to encapsulated cell products, compositions comprising the same and uses thereof to treat diabetes, and related complications, increase islet cell masses, improve a metabolic profile in a subject, and other related conditions. Processes to produce the encapsulated islet cell product are described.

The invention provides a plant differential metabolite fast-screening method based on UPLC-QTOF. The method comprises acquiring information of chemical constituents in the plant through an UPLC-QTOF modern analytical technology, extracting substance information through a non-target metabolic profile analysis technology, carrying out chromatographic peak extraction and in-source pyrolysis molecular fragment clustering, carrying out between-sample time drifting correction through a dynamic planning method, carrying out between-sample substance registration according to a self-adaptive network link method and screening sample different metabolites through statistical analysis.

The invention discloses an establishing method for a lung cancer characteristic metabolite fingerprint spectrum in urine. The gas chromatography and mass spectrum combined technology is adopted to detect metabolic profiles of urine samples of lung cancer patients and healthy donors, and is combined with the biological method of a support vector machine to build a smoker lung cancer metabolite fingerprint spectrum and a non-smoker lung cancer metabolite fingerprint spectrum, wherein the smoker lung cancer metabolite fingerprint spectrum comprises oxalic acid, phosphoric acid, uracil, threonine, 5-pidolic acid, citric acid and galactose or comprises phosphoric acid, uric acid, citric acid and oxalic acid; and the non-smoker lung cancer metabolite fingerprint spectrum comprises alanine, oxalic acid, phosphoric acid, uracil, serine, threonine, 5-pidolic acid, ribose, aconitate, citric acid, galactose, tyrosine, palmitic acid and stearic acid. The method can detect only needing the urine samples, satisfies the requirements of effectiveness, simplicity and feasibility in the operation aspect, and is suitable for large-scale application.

The invention discloses an intracellular metabolic profiling high-flux analysis method of a few of cells (with the number of 103-104). The method comprises simple and efficient cell quenching and metabolite extraction, metabolite derivatization and mass spectrometric detection. The intracellular metabolic profiling high-throughput analysis method has the characteristics of simpleness, fastness, high sensitivity and good repeatability and is suitable for high-throughput analysis of metabolome of cells cultured through a 96-well plate and cells with a low yield, wherein the analysis fields comprise drug large-scale screening, evaluation and stem cell research.

Provided herein is a system and method for analyzing microarray data (transcriptome profiles), metabolite data (metabolome profiles), protein level data (proteome profiles), or any combination thereof to determine the biochemical pathways affected by a treatment. The system and method can be used to generate biochemical pathway information for any organism for which metabolic profile data can be obtained. The system and method may allow users to query the pathways generated and to filter the results of queries based on the -omic profile data, pathways involving molecules of interest, notions of biochemical importance, milestone molecules, and other factors. The system and method may also be suitable for discovery of regulatory sequences in genes. In an exemplary use, the system and method can be utilized to identify three genes involved in “de novo” ammonia “biosynthesis” that are induced by light, and was able to identify a putative cis-element, GWTTGTGG, that is likely involved in the regulation of those genes.

A urine test for diagnosing lung cancer has been developed that uses an artificial nose such as a colorimetric sensor arrays to identify metabolic profiles in urine headspace gas. Cancer cells excrete unique compounds that are a byproduct of their metabolism. The compounds are excreted through a patient's endocrine system by filtration through the kidneys and other organs and are ultimately excreted through the urine. Some of these cancer cell by-products excrete in the urine are small volatile organic compounds (VOCs). Once the urine has exited the body, these VOCs may be outgassed to the environment. Experimental research has determined that a colorimetric sensor array as disclosed is capable of reliably identifying patients with lung cancer based after exposure to the VOCs of the urine headspace gas.

The invention relates to a method for evaluating the cytotoxicity of environmental pollutants. The method adopts a HepG2 cell as a test cell and comprises the following steps: (a) establishing a pretreatment method for extracting metabolites from a cell culture fluid rapidly; (b) analyzing the 23 metabolites in the cell culture fluid quantitatively by adopting HPLC-MS/MS (high performance liquid chromatography and mass spectrometry or mass spectrometry); (c) establishing the metabolic profile chart of the HepG2 cell; and (d) analyzing the influence of the environmental pollutants on all the metabolic pathways of the HepG2 cell successfully by adopting a metabolic flux analysis system according to data obtained by adopting the HPLC-MS/MS. The pretreatment method is simple, various metabolites in the cell culture fluid can be quantitated accurately by adopting the HPLC-MS/MS, and the influence of the environmental pollutants on the metabolic pathways of the HepG2 cell can be reflected intuitively by combining the metabolic flux analysis system. The method provided by the invention has the advantages of simple operation, short analysis time, high sensitivity, good reproducibility and the like, and comprehensive information can be obtained.

The present invention provides a metabolic profile, a database comprising a metabolic profile, a method for determining a metabolic profile, uses for a metabolic profile, and warfarin metabolites.

The invention belongs to the technical field of metabonomics, and provides Xiaoyao San metabolic markers in a biological sample, and a detection method and an application thereof. A pharmacological action mechanism of Xiaoyao San for treating depression is defined. The metabolic markers are 4-oxo hex-2-ene dioic acid, creatinine, L-cystathionine and acetylphosphate. A UPLC-Q-TOF/MS technology is adopted for analyzing the plasma and metabolic profile change of patients in a drug administration group and a control group of the Xiaoyao San, and then a multivariate statistical analysis method and an orthogonal partial least square discriminant analysis (OPLS-DA) method are adopted for screening the changes of the metabolic markers of the Xiaoyao San after 8-week treatment. The study is used as a first clinical metabonomics study of the Xiaoyao San; the influence of the metabolic level of the Xiaoyao San is found; the action mechanism of the Xiaoyao San is preliminarily illuminated in metabolic pathway; and a new method is provided for predicting the pharmacological mechanism of the Xiaoyao San for treating the depression.

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and/or lab test data collected for the patient. The platform encodes the biosignals into a vector representation and inputs the vector representation into a patient-specific metabolic model to determine a metabolic state of the patient at a conclusion of the current time period. The patient-specific metabolic model comprises a set of parameter values determined based on labels assigned to the previous metabolic states and a function representing one or more effects of the plurality of biosignals of the personalized metabolic profile. The platform compares the determined metabolic state of the patient to a threshold metabolic state representing a target metabolism. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve the determined metabolic state to the functional metabolic state.

Embodiments include methods for generating a metabolite profile of a stool sample and methods of assessing the status of a subject using the metabolic profile derived from a stool sample.

The invention discloses a method of screening a marker of acute renal toxicity caused by aristolochic acid by utilizing cell metabolic profiling in vitro. The effective dose causing renal cell damage is determined by adopting a 3-(4,5-dimethylthiahiazo-2)-2,5-diphenytetrazoliumromide (MTT) staining manner. Renal cell metabolites are analyzed by adopting an ultra-high performance liquid chromatography-mass chromatography technique to obtain metabolic profiles. Metabolic profile data of normal groups and medicine damage groups are analyzed by adopting a multivariate statistic method. A potential renal toxicity marker is screened by combining a change rule of metabolites along with medicine acting time. The screened marker is good in predicting performance. The average accuracy of outer verification is 90% or above. The method comprehensively represents variation situations of metabolites of normal renal cells under medicine damages, and can provide technique supports for early diagnosis of renal toxicity caused by medicines or medicine safety evaluation.

The invention provides a method for predicting a mechanism for treating diabetic nephropathy through gandi capsules on the basis of metabolites in hematuria. The mechanism is characterized by comprising the following specific steps: S1, selecting an experimental group and a control group according to the ratio of 1: 1; S2, collecting to-be-tested samples at regular intervals; S3, treating the samples in step S2, and carrying out UPLC-Q-TOF/MS separation and analysis; S4, carrying out metabolic profiling analysis on UPLC-Q-TOF/MS atlas data obtained in step S3 to obtain a data set; S5, constructing a PLS-DA model according to the data set obtained in step S4; S6, screening out metabolism markers capable of distinguishing a blank group from a gandi capsule administration group according to an S-PLOT load diagram and a VIP score of the model constructed in step S5; and S7, carrying out enrichment analysis on the metabolism markers which are obtained by screening in step S6 through an IPAanalysis method, and sequencing the metabolism markers according to enrichment efficiency. By the method, the pharmacological mechanism for treating the diabetic nephropathy through the gandi capsulescan be predicted.

A method is provided for controlling a metabolic profile of an anaerobic microbial fermentation culture. In particular, a metabolic profile of a fermentation process is controlled by controlling the amount of dissolved CO2 provided to a culture. Further provided is a method of producing one or more products by microbial fermentation of a gaseous substrate through feeding tail gas CO2 from a reactor to a second reactor, or by recycling tail gas CO2 to the same reactor.

The invention relates to a method for obtaining the metabolic difference between genetically modified and non-genetically modified maize based on UHPLC-MS (Ultra High Performance Liquid Chromatography-Mass Spectrometer). According to the method, the extract of maize leaves is analyzed by adopting an ultra high performance liquid chromatography-high resolution mass spectrometry analysis platform toobtain metabolic profiles of the maize leaves, and then the data of the genetically modified and non-genetically modified maize is differentiated according to a multivariate statistical method to obtain compounds having important contribution to the phenotypic difference in metabolism. The method is simple to operate, capable of carrying out high throughput detection and high in detection resolution in particular, can eliminate interference, realizes efficient and reliable metabolite information identification and is more authentic and reliable in obtained result. The method can provide a basis for further study on the safety of the genetically modified maize.

The invention provides a method for screening a hepatic disease marker from a body fluid metabolic profile using a chain multi-population genetic algorithm, belonging to the data mining and metabonimics technical field. The method is characterized by comprising the following steps: firstly, analyzing body fluid metabolites using a liquid chromatograph-mass spectrometer (LC-MS) to obtain the metabolic profile, carrying out multi-population parallel evolution to obtain a plurality of feature subsets with strong discrimination capability, and measuring significance of features according to the frequency that the features appear in the subsets; secondly, searching from front to back according to the significance of the features sequentially to screen out the marker showing three-stage specificity of hepatic disease; and finally carrying out information interaction between adjacent populations during the evolution to avoid a premature defect of the genetic algorithm. Meanwhile, the invention further provides a new crossover operation to ensure that any chromosome does not contain the same feature. The method can help efficiently and accurately screen out the relevant markers in three stages of hepatic disease, thus achieving high precision and good stability; and 10-fold cross validation for a SVM model constructed by the screened features can achieve up to 97.9% in high precision.